News
LPCN
2.110
+0.96%
0.020
Weekly Report: what happened at LPCN last week (0810-0814)?
Weekly Report · 4d ago
Weekly Report: what happened at LPCN last week (0803-0807)?
Weekly Report · 08/10 09:54
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), Lipocine (LPCN) and High Tide (HITI)
TipRanks · 08/05 12:50
Lipocine GAAP EPS of -$0.32, revenue of $190M
Seeking Alpha · 08/04 17:08
*Lipocine 2Q Loss/Shr 32c >LPCN
Dow Jones · 08/04 12:06
*Lipocine 2Q Research and Development Expenses $2.0M >LPCN
Dow Jones · 08/04 12:06
Press Release: Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026
Dow Jones · 08/04 12:00
Press Release: Lipocine Announces Financial -2-
Dow Jones · 08/04 12:00
Lipocine: Q2 Earnings Snapshot
Barchart · 08/04 05:21
Lipocine Appoints Industry Veteran Grissinger to Board
TipRanks · 08/03 13:57
*Lipocine Appoints Michael J. Grissinger to Bd of Directors
Dow Jones · 08/03 12:01
Press Release: Lipocine Appoints Michael J. Grissinger to Board of Directors
Dow Jones · 08/03 12:00
Weekly Report: what happened at LPCN last week (0727-0731)?
Weekly Report · 08/03 09:54
Weekly Report: what happened at LPCN last week (0720-0724)?
Weekly Report · 07/27 09:57
Weekly Report: what happened at LPCN last week (0713-0717)?
Weekly Report · 07/20 09:54
Weekly Report: what happened at LPCN last week (0706-0710)?
Weekly Report · 07/13 09:56
Weekly Report: what happened at LPCN last week (0629-0703)?
Weekly Report · 07/06 09:58
Weekly Report: what happened at LPCN last week (0622-0626)?
Weekly Report · 06/29 09:55
Weekly Report: what happened at LPCN last week (0615-0619)?
Weekly Report · 06/22 10:01
Weekly Report: what happened at LPCN last week (0608-0612)?
Weekly Report · 06/15 10:02
More
Webull provides a variety of real-time LPCN stock news. You can receive the latest news about Lipocine Inc through multiple platforms. This information may help you make smarter investment decisions.
About LPCN
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics. The Company’s clinical development candidates include: LPCN 1154, oral brexanolone, for the treatment of postpartum depression, LPCN 2101, for the treatment of epilepsy, LPCN 2203, an oral candidate targeted for the management of essential tremor, LPCN 2401, an oral proprietary anabolic androgen receptor agonist for improved body composition in obesity management, and LPCN 1148, for the management of decompensated cirrhosis. It is also developing LPCN 1107, for the prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, and LPCN 1144, for the treatment of metabolic dysfunction-associated steatohepatitis. Its product candidate, TLANDO, is a novel oral prodrug of testosterone containing testosterone undecanoate developed by the Company.